Deferasirox

ApprovedTerminated

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Myelodysplastic Syndrome

Conditions

Myelodysplastic Syndrome, Transfusional Iron Overload

Trial Timeline

Dec 1, 2011 → Sep 1, 2012

NCT ID

NCT01326845

About Deferasirox

Deferasirox is a approved stage product being developed by Novartis for Myelodysplastic Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT01326845. Target conditions include Myelodysplastic Syndrome, Transfusional Iron Overload.

What happened to similar drugs?

6 of 18 similar drugs in Myelodysplastic Syndrome were approved

Approved (6) Terminated (6) Active (7)

✅decitabine + azacitidineEisaiApproved

✅DeferasiroxNovartisApproved

✅ICL670/DeferasiroxNovartisApproved

✅deferasiroxNovartisApproved

✅DeferasiroxNovartisApproved

✅Epoetin betaRocheApproved

❌Placebo + Epoetin alfa + Placebo + Epoetin alfaJohnson & JohnsonPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03387475	Phase 2	Completed	Feb 20, 2018	Oct 1, 2024	Myelodysplasia
NCT03372083	Approved	Completed	Jan 16, 2018	Dec 5, 2019	Iron Overload
NCT02943668	Phase 2	Terminated	Mar 2, 2017	Dec 17, 2018	Anemia
NCT02720536	Phase 3	Completed	Aug 16, 2016	Jul 23, 2019	Chronic Iron Overload
NCT02663752	Phase 2	Terminated	May 30, 2016	Jul 1, 2016	Myelodysplastic Syndrome
NCT02069886	Approved	Withdrawn	Dec 1, 2014	Dec 1, 2018	Thalassemia (Transfusion Delendent)
NCT01948817	Phase 2	Withdrawn	Feb 1, 2014	Feb 1, 2016	Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD
NCT01724138	Approved	Withdrawn	Jun 1, 2013	Oct 1, 2014	β-thalassemia Major
NCT01709838	Approved	Completed	Dec 6, 2012	Jan 17, 2019	Non-transfusion Dependent Thalassemia
NCT01326845	Approved	Terminated	Dec 1, 2011	Sep 1, 2012	Myelodysplastic Syndrome
NCT01394029	Pre-clinical	Completed	Jul 1, 2011	Oct 1, 2015	Transfusional Hemosiderosis
NCT01250951	Approved	Completed	Dec 1, 2009	Sep 1, 2011	Myelodysplastic Syndrome
NCT00981370	Phase 3	Terminated	Apr 1, 2009	Dec 1, 2010	Anemia, Sickle Cell
NCT00879242	Phase 2	Completed	Feb 1, 2009	—	Beta Thalassemia Transfusion Dependent
NCT01335035	Approved	Completed	Dec 1, 2008	—	Iron Overload
NCT00654589	Approved	Completed	Feb 1, 2008	Jan 1, 2012	Iron Overload
NCT00599326	Phase 3	Completed	Jan 1, 2008	Apr 1, 2010	Porphyria Cutanea Tarda
NCT00564941	Approved	Completed	Dec 1, 2007	Jul 1, 2011	Myelodysplastic Syndromes
NCT00673608	Approved	Completed	Nov 1, 2007	Sep 1, 2011	Hemoglobinopathies
NCT00560820	Phase 1	Completed	Sep 1, 2007	Apr 1, 2012	β-thalassemia

Competing Products

20 competing products in Myelodysplastic Syndrome

See all competitors

Product	Company	Stage	Hype Score
NEX-18a injection + Azacitidine Injection	Nanexa AB	Phase 1	23
JSP191	Jasper Therapeutics	Phase 1	11
Humanized anti-CD117 Monoclonal Antibody (JSP191)	Jasper Therapeutics	Phase 1	15
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II	GT Biopharma	Phase 1/2	14
Erlotinib Hydrochloride	Astellas Pharma	Phase 2	35
Decitabine + Decitabine + Decitabine	Eisai	Phase 2	35
Decitabine + Valproic Acid	Eisai	Phase 2	35
decitabine + decitabine	Eisai	Phase 2	35
decitabine + azacitidine	Eisai	Approved	35
Decitabine	Eisai	Phase 2	27
decitabine + decitabine + decitabine + decitabine	Eisai	Phase 1	29
Decitabine, Arsenic Trioxide and Ascorbic Acid	Eisai	Phase 2	35
Subcutaneous Decitabine	Eisai	Phase 1	21
Decitabine	Eisai	Phase 2	35
Galunisertib + Placebo	Eli Lilly	Phase 2/3	38
DSP-7888	Sumitomo Pharma	Phase 1/2	32
TP-0184	Sumitomo Pharma	Phase 1/2	24
Decitabine	Johnson & Johnson	Phase 2	35
Epoetin alfa	Johnson & Johnson	Phase 2	27
ZARNESTRA, tipifarnib, R115777	Johnson & Johnson	Phase 2	35